Skip to content

Codiak BioSciences, Inc.

Delisted

CIK 1659352fmd_1QV5YNCJWQ3EW5FCGTF0462QJ8Manufacturing · Biological Products, (No Diagnostic Substances)Template: Standard

Coverage: Jan 01, 2019 to Sep 30, 2022, 13 periods

Latest annual · FY2021

Millions
Total revenues
23
Operating income
(70)
Net income
(37)
Free cash flow
(77)

Latest quarter · Q3 FY2022

Millions
Total revenues
1
Operating income
(21)
Net income
(19)
Free cash flow
(10)
Open Financials

Codiak BioSciences, Inc. financials: quick answers

Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.

MetricFY2021FY2020ChangeSource
Revenue$22.9 million$2.9 million+686.8%10-K 2022-03-10 · proof
Operating income-$69.5 million-$90.9 million10-K 2022-03-10 · proof
Net income-$37.2 million-$91.7 million10-K 2022-03-10 · proof
Cash from operating activities-$74.1 million-$63.4 million10-K 2022-03-10 · proof
Free cash flow-$77.4 million-$84.4 million10-K 2022-03-10 · proof
Total assets$171.7 million$151.3 million+13.4%10-K 2022-03-10 · proof
Total liabilities$118.2 million$136.8 million-13.6%10-K 2022-03-10 · proof
Cash and cash equivalents$76.9 million$88.9 million-13.5%10-K 2022-03-10 · proof
What was Codiak BioSciences, Inc.'s revenue in fiscal 2021?
Codiak BioSciences, Inc. reported revenue of $22.9 million for fiscal 2021 (the year ended Dec 31, 2021), against $2.9 million the year before (+686.8%). Source: the 10-K filed with the SEC on Mar 10, 2022. SEC
What was Codiak BioSciences, Inc.'s operating income in fiscal 2021?
Codiak BioSciences, Inc. reported operating income of -$69.5 million for fiscal 2021 (the year ended Dec 31, 2021), against -$90.9 million the year before. Source: the 10-K filed with the SEC on Mar 10, 2022. SEC
What was Codiak BioSciences, Inc.'s net income in fiscal 2021?
Codiak BioSciences, Inc. reported net income of -$37.2 million for fiscal 2021 (the year ended Dec 31, 2021), against -$91.7 million the year before. Source: the 10-K filed with the SEC on Mar 10, 2022. SEC
What was Codiak BioSciences, Inc.'s cash from operating activities in fiscal 2021?
Codiak BioSciences, Inc. reported cash from operating activities of -$74.1 million for fiscal 2021 (the year ended Dec 31, 2021), against -$63.4 million the year before. Source: the 10-K filed with the SEC on Mar 10, 2022. SEC
What was Codiak BioSciences, Inc.'s free cash flow in fiscal 2021?
Codiak BioSciences, Inc. reported free cash flow of -$77.4 million for fiscal 2021 (the year ended Dec 31, 2021), against -$84.4 million the year before. Source: the 10-K filed with the SEC on Mar 10, 2022. SEC
What are Codiak BioSciences, Inc.'s total assets?
As of Dec 31, 2021, Codiak BioSciences, Inc. reported total assets of $171.7 million, against $151.3 million a year earlier (+13.4%). Source: the 10-K filed with the SEC on Mar 10, 2022. SEC
What are Codiak BioSciences, Inc.'s total liabilities?
As of Dec 31, 2021, Codiak BioSciences, Inc. reported total liabilities of $118.2 million, against $136.8 million a year earlier (-13.6%). Source: the 10-K filed with the SEC on Mar 10, 2022. SEC
What are Codiak BioSciences, Inc.'s cash and cash equivalents?
As of Dec 31, 2021, Codiak BioSciences, Inc. reported cash and cash equivalents of $76.9 million, against $88.9 million a year earlier (-13.5%). Source: the 10-K filed with the SEC on Mar 10, 2022. SEC

Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.

The same numbers for an agent, with proof on every value:

curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1659352&period_type=annual&limit=5"

Information only, not investment advice.